Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

17.0K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influenza A virus replicates productively in primary human kidney cells and induces factors and mechanisms related to regulated cell death and renal pathology observed in virus-infected patients.

Frontiers in cellular and infection microbiologyยท2024
Same author

HIV-1 Infection of Long-Lived Hematopoietic Precursors In Vitro and In Vivo.

Cellsยท2022
Same author

Phage Display-Directed Discovery of LEDGF/p75 Binding Cyclic Peptide Inhibitors of HIV Replication.

Molecular therapy : the journal of the American Society of Gene Therapyยท2021
Same author

Lactobacilli Expressing Broadly Neutralizing Nanobodies against HIV-1 as Potential Vectors for HIV-1 Prophylaxis?

Vaccinesยท2020
Same author

Lectin Affinity Plasmapheresis for Middle East Respiratory Syndrome-Coronavirus and Marburg Virus Glycoprotein Elimination.

Blood purificationยท2018
Same author

The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses.

Virusesยท2018

Related Experiment Video

Updated: Dec 29, 2025

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

10.7K

Advances in Antibody-Based HIV-1 Vaccines Development.

Ursula Dietrich1

  • 1Georg-Speyer-Haus, Institute of Tumor Biology and Experimental Therapy, Paul-Ehrlich-Str. 42-44, 60596 Frankfurt, Germany.

Vaccines
|January 30, 2020
PubMed
Summary
This summary is machine-generated.

An effective HIV-1 vaccine is crucial for ending the epidemic, despite advances in antiretroviral therapy. Research continues to develop a preventative vaccine to combat the global spread of HIV.

More Related Videos

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

7.9K
Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
07:10

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

14.6K

Related Experiment Videos

Last Updated: Dec 29, 2025

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

10.7K
Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

7.9K
Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
07:10

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

14.6K

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Antiretroviral therapy (ART) has significantly improved HIV-1 treatment and prevention.
  • A curative or broadly protective vaccine remains an unmet medical need to eradicate HIV-1 infection globally.

Discussion:

  • The development of an effective HIV-1 vaccine is complex due to the virus's genetic diversity and ability to evade immune responses.
  • Current research focuses on various vaccine strategies, including mRNA, viral vectors, and protein-based approaches.

Key Insights:

  • Suboptimal immune responses elicited by current vaccine candidates hinder progress.
  • Understanding correlates of protection is essential for rational vaccine design.

Outlook:

  • Continued investment in HIV-1 vaccine research is vital.
  • Novel immunogens and delivery systems may overcome existing challenges.
  • Collaborative global efforts are necessary to accelerate vaccine development and achieve epidemic control.